Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Z-ligustilide is a natural phthalide compound, specifically an enol ester and benzoquinone derivative, found in various traditional Chinese medicinal plants, most notably Angelica sinensis (Danggui) and Ligusticum chuanxiong. It exhibits a range of pharmacological activities including neuroprotection, antioxidant, anti-inflammatory, and anticancer properties. Mechanistically, it is neuroprotective by activating the Nrf2-TrxR signaling axis, which promotes endogenous antioxidant capacity and drives microglial polarization toward the M2 (anti-inflammatory) phenotype, providing benefit in models of Parkinson's disease. In cancer cells, it induces apoptosis via ER stress signaling, c-Myc activation, and modulation of NRF2-related pathways. Preclinical studies indicate additional effects in models of depression, osteoarthritis, and inflammation, but Z-ligustilide is not an approved pharmaceutical and is primarily used in research or as a constituent of traditional herbal formulations[1][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on z-ligustilide.